Alison M. Schram
Medical oncologist at Memorial Sloan Kettering who runs first-in-human cancer drug trials, including the first trial of RMC-5552, an mTORC1-selective inhibitor
Associate Attending Physician, Gynecologic Medical Oncology and Early Drug Development, Memorial Sloan Kettering Cancer Center · fellowship in medical oncology, Memorial Sloan Kettering · residency in internal medicine, Brigham and Women's Hospital · MD, University of Pennsylvania
Rapamycin and the related rapalogs only partly block mTORC1, and the newer drugs that fully block mTOR also hit mTORC2, which causes high blood sugar and other side effects. RMC-5552 was designed to do better on both counts: it is a bi-steric drug that binds two sites on mTOR at once and is selective for mTORC1. Alison Schram was first author of the 2025 phase 1 trial in Clinical Cancer Research (SCH2025), the first time the drug was given to people. Fifty-seven patients with advanced solid tumours received rising weekly doses. Treatment-related high blood sugar occurred in only 4 percent of them and never limited the dose, and 64 percent had their disease controlled for a time.
These numbers fit the idea that sparing mTORC2 reduces metabolic side effects. The trial had no comparison group and did not test RMC-5552 against rapamycin or an older mTOR blocker, so it is early evidence and cannot show that sparing mTORC2 is the reason.
Schram studied medicine at the University of Pennsylvania, trained in internal medicine at Brigham and Women's Hospital in Boston and in medical oncology at Memorial Sloan Kettering. At MSK the work centres on early-phase clinical trials that match new drugs to the molecular changes driving a patient's tumour, in the Early Drug Development Service and in gynecologic medical oncology, where Schram is an associate attending physician.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2025 | H | The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial SCH2025 First author: reported the first-in-human dose-escalation trial of the mTORC1-selective inhibitor RMC-5552 in 57 patients with advanced solid tumours. |
Co-authors in the Atlas 3
People with a profile here who share at least one study with Alison M. Schram.
ShowHide
- Howard A Burris Medical oncologist who led the Sarah Cannon Research Institute in Nashville as President and Chief Medical Officer, has run hundreds of early-phase cancer drug trials, including the first trial of the mTORC1-selective inhibitor RMC-5552, and was ASCO President in 2019–2020
- Justin G. Meyerowitz Industry scientist on the team that developed RMC-5552, a bi-steric inhibitor selective for mTORC1
- Yu Chi Yang Scientist at Revolution Medicines who worked on the company's bi-steric mTORC1-selective inhibitors, from the breast cancer lab studies of RMC-6272 to the first trial of RMC-5552 in patients
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.